uniQure (NASDAQ:QURE) Stock Price Down 4.8% - Here's What Happened

uniQure (NASDAQ:QURE - Get Free Report) shares were down 4.8% during mid-day trading on Tuesday . The company traded as low as $15.08 and last traded at $15.05. Approximately 74,702 shares changed hands during trading, a decline of 93% from the average daily volume of 1,144,552 shares. The stock had previously closed at $15.80.

Analyst Ratings Changes

QURE has been the subject of a number of recent analyst reports. StockNews.com raised uniQure to a "sell" rating in a report on Wednesday, December 11th. Leerink Partners upped their price target on shares of uniQure from $26.00 to $44.00 and gave the stock an "outperform" rating in a report on Wednesday, December 11th. Mizuho upped their target price on uniQure from $7.00 to $20.00 and gave the stock a "neutral" rating in a research note on Thursday, December 19th. The Goldman Sachs Group lifted their price target on uniQure from $9.00 to $20.00 and gave the company a "neutral" rating in a research report on Thursday, December 12th. Finally, Cantor Fitzgerald boosted their price target on shares of uniQure from $28.00 to $58.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, uniQure currently has a consensus rating of "Moderate Buy" and an average price target of $40.00.

uniQure Stock Performance

The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a fifty day moving average price of $13.31 and a 200 day moving average price of $8.84. The stock has a market cap of $746.70 million, a PE ratio of -3.09 and a beta of 0.41.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analysts' expectations of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. Analysts expect that uniQure will post -3.74 earnings per share for the current year.

Insider Activity at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares in the company, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.74% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of QURE. China Universal Asset Management Co. Ltd. raised its holdings in uniQure by 9.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock worth $195,000 after acquiring an additional 969 shares during the last quarter. Sanders Morris Harris LLC boosted its position in shares of uniQure by 50.0% during the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company's stock valued at $1,803,000 after buying an additional 34,034 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in uniQure in the 4th quarter worth about $88,000. Franklin Resources Inc. purchased a new position in uniQure in the 3rd quarter worth about $7,360,000. Finally, Geode Capital Management LLC lifted its stake in uniQure by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company's stock valued at $2,509,000 after acquiring an additional 6,362 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.